



17157 U.S. PTO

37 C.F.R. 1.53b APPLICATION
Continuation or Divisional
Page 1 of 3

Case No. S03300/1B/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Anticipated Classification of This Application:
Prior Application: Examiner Paul A. Zucker and Art Unit 1621

THE COMMISSIONER OF PATENTS AND TRADEMARKS
P.O. BOX 1450
ALEXANDRIA, VA 22313

Sir:

Transmitted herewith for filing is a divisional application under 35 U.S.C. § 121, and 37 C.F.R 1.53b, of pending prior Application Serial Number 10/321,969 filed December 17, 2002, which is a divisional application of prior Application Serial Number 09/816,575, filed on March 23, 2001 U.S. Patent Number 6,586,474 which claims the benefit of priority of U.S. Provisional Patent Application No. 60/191,923 filed March 24, 2000 of Richard C. Durley entitled AMIDINO COMPOUNDS USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS.

Enclosed is a copy of the application, including a copy of the Declaration and Power of Attorney as originally filed July 17, 2001 and a copy of the assignment as originally filed June 6, 2002. I hereby verify that the attached papers are a true copy of said prior application.

Cancel in this application, original Claims ____ of the prior application before calculating the filing fee. (At least one original, independent claim must be retained for filing purposes)

Amend the specification by inserting before the first line the sentence: This application is a division of U.S. serial No. 10/321,969, filed December 17, 2002, which is a division of U.S. serial No. 09/816,575, filed March 23, 2001, U.S. Patent No. 6,586,474, which claims the benefit of priority of U.S. Provisional Patent Application No. 60/191,923 filed March 24, 2000, herein incorporated by reference.

A preliminary amendment is enclosed.

The filing fee is calculated below:

Basic Filing Fee [37 CFR 1.16(a)]				\$770.00
Additional Filing Fee [37 CFR 1.16(b), (c)]				
Claims	No. Filed	No. Extra	Rate	
Independent	2-3 = --	--	X \$86.00 =	--
Total	18-20= --	--	X \$18.00 =	--
				\$770.00
TOTAL FEE:				

22358 U.S. PTO
10/815375
040104

A triplicate copy of this transmittal paper is enclosed.

Please charge the above-calculated total fee to Deposit Account No. 19-1025.

The Commissioner is hereby authorized and requested to charge any fees in addition to the above as well as all future fees set forth in 37 CFR 1.16 and 1.17 which may be required during the entire pendency of this Application, and credit any overcharges to Deposit Account No. 19-1025 [37 CFR 1.25(b)].

NOTE: THIS AUTHORIZATION DOES NOT INCLUDE FEES REQUIRED UNDER 37 CFR 1.18

Transfer the drawings from the prior application to this application and abandon said prior application as of the filing date accorded this application. ANOTHER DUPLICATE COPY OF THIS SHEET IS ENCLOSED FOR FILING IN THE PRIOR APPLICATION FILE.

New formal drawings are enclosed.

Priority of Application Serial No. _____, filed on _____ in _____ (country) is claimed under 35 U.S.C. 119.

The certified copy of the priority application has been filed in prior Application Serial No. _____, filed _____.

The prior application is assigned of record to Pharmacia Corporation, 800 N. Lindbergh, St. Louis, MO 63167.

The Power of Attorney in the prior application is to Philip B. Polster II, Registration Number 43,864.

The power appears in the original papers in the prior application.

Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.

Enclosed is a copy from the prior application of the Associate Power of Attorney from James M. Warner to Philip B. Polster, II.

Address all future communications to:

Pfizer Corporate Patent Department
P.O. Box 1027
Chesterfield, Missouri 63006

The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date:

1 April 2004

Customer No. 26648


Philip B. Polster, II
Attorney for Applicants
Registration No. 43,864
314-274-9094 (St. Louis)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

 Applicant claims small entity status. See 37 CFR 1.27TOTAL AMOUNT OF PAYMENT (\$)
\$770.00

Complete if Known

Application Number	TBD
Filing Date	4/1/2004
First Named Inventor	Webber et al
Examiner Name	Paul Zucker
Art Unit	1621
Attorney Docket No.	S03300/IB/US

METHOD OF PAYMENT (check all that apply)

 Check Credit card Money Other None
 Deposit Account:
Deposit Account Number **19-1025**Deposit Account Name **Pharmacia Corporation**

The Director is authorized to: (check all that apply)

 Charge fee(s) indicated below Credit any overpayments Charge any additional fee(s) or any underpayment of fee(s) Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION (continued)


3. ADDITIONAL FEES

Large Entity	Small Entity	Fee Description	Fee Paid
Fee Code (\$)	Fee Code (\$)	Fee Description	
1051 130	2051 65	Surcharge - late filing fee or oath	
1052 50	2052 25	Surcharge - late provisional filing fee or cover sheet	
1053 130	1053 130	Non - English specification	
1812 2,520	1812 2,520	For filing a request for ex parte reexamination	
1804 920*	1804 920*	Requesting publication of SIR prior to Examiner action	
1805 1,840*	1805 1,840*	Requesting publication of SIR after Examiner action	
1251 110	2251 55	Extension for reply within first month	
1252 420	2252 210	Extension for reply within second month	
1253 950	2253 475	Extension for reply within third month	
1254 1,480	2254 740	Extension for reply within fourth month	
1255 2,010	2255 1,005	Extension for reply within fifth month	
1401 330	2401 165	Notice of Appeal	
1402 330	2402 165	Filing a brief in support of an appeal	
1403 290	2403 145	Request for oral hearing	
1451 1,510	1451 1,510	Petition to institute a public use proceeding	
1452 110	2452 55	Petition to revive - unavoidable	
1453 1,330	2453 665	Petition to revive - unintentional	
1501 1,330	2501 665	Utility issue fee (or reissue)	
1502 480	2502 240	Design issue fee	
1503 640	2503 320	Plant issue fee	
Total Claims 14 -20** = 0 X 0.00			
Independent Claims 1 - 3** = 0 X 0.00			
Multiple Dependent			
Large Entity	Small Entity	Fee Description	
Fee Code (\$)	Fee Code (\$)	Fee Description	
1202 18	2202 9	Claims in excess of 20	
1201 86	2201 43	Independent claims in excess of 3	
1203 290	2203 145	Multiple dependent claim, if not paid	
1204 86	2204 43	** Reissue independent claims over original patent	
1205 18	2205 9	** Reissue claims in excess of 20 and over original patent	
SUBTOTAL (1)	(\$)	\$770.00	
Extra Claims	Fee from below	Fee Paid	
Total Claims 14 -20** = 0 X 0.00			
Independent Claims 1 - 3** = 0 X 0.00			
Multiple Dependent			
Other fee (specify)			
SUBTOTAL (2)	(\$)	\$0.00	
*Reduced by Basic Filing Fee Paid			SUBTOTAL (3) (\$)

**or number previously paid, if greater; For Reissues, see above

SUBMITTED BY

Complete (if applicable)

Name (Print/Type)	Philip B. Polster, II	Registration No. (Attorney/Agent)	43,864	Telephone	314-274-9094
Signature				Date	4/1/2004

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)

Applicant(s): Webber et al

Docket No.


S03300/1B/US

Serial No.
TBDFiling Date
4/1/2004Examiner
Paul ZuckerGroup Art Unit
1621Invention: **AMIDINO COMPOUNDS USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS**

I hereby certify that the following correspondence:

116 Pgs of Description, 1 Pg. of Abstract, 4 Pgs. of Claims, Postcard, Copy of Executed Declaration, Copy of Recorded Assignment, Fee Transmittal, Patent Application Transmittal Letter*(Identify type of correspondence)*

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

4/1/2004*(Date)***Michelle R. Becker***(Typed or Printed Name of Person Mailing Correspondence)**(Signature of Person Mailing Correspondence)***EU 589383735 US***("Express Mail" Mailing Label Number)*

Note: Each paper must have its own certificate of mailing.